🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The #UromigosLive #BladderCancer Poll 3: We have come a long way in drug dev in #BladderCancer since the 1st approval of IO in 2016! Tx paradigm in 2022 (1/3)👇 Tom Powles Jonathan Rosenberg MD Brian Rini, MD

Great to see our article on Intracorporeal Neobladder featured on the cover of J Endourol. Hope the detailed description + didactic video will be helpful to urologist learning this approach. Dr. John Sfakianos Reza Mehrazin, MD Mount Sinai Department of Urology liebertpub.com/doi/10.1089/en…

#Twittorial on our recent @IBCG on risk stratifying intermediate risk NMIBC now in print in European Urology Oncology #bladdercancer #MedTwitter #UroSoMe doi.org/10.1016/j.euo.…

Great start for McGill #Urology Research Day. Dr Marshall Stoller gives an excellent talk on novel understanding etiology of urinary stones…delivering an engaging and exciting talk, even for a urologic oncologist:) McGill University UCSFUrology UC San Francisco Fadl Hamouche MD, FRCSC Simon Tanguay

JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The IMDC does it again ! #IMDC Daniel Heng with Talal El Zarif, MD Ziad Bakouny, MD, MSc Shaan Dudani et al in European Urology secure-web.cisco.com/1nOqqWr2rKW30O…

Congratulations Charles Hesswani for receiving Northeastern Section award for his research on external validation of molecular subtyping classifier using immunohistochemistry in #mibc patients treated with #radiation David M. Berman McGill University @NCICCR_UroOnc

Very interesting 🧵

big news in RCC-hot off the press!!positive trial for CA9 pet/ct! thrilled to have our UCLA team be lead site. first of MANY initiatives- congrats to Telix Pharmaceuticals team and special thanks to our patients. UCLA Urology Kidney Cancer . Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Toni Choueiri, MD

Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Robert Motzer MD Hans Hammers

IMDC favorable risk RCC after #ASCO2023. Similar to ITT, early disease control for IO/TKI regimens and durability for Ipi/Nivo showing some favorable risk pts are immune-responsive. Biomarkers to select and to de-intensify treatment are needed. Uromigos Sumanta K. Pal, MD, FASCO Toni Choueiri, MD

New table of IO doublets in sarcomatoid RCC: 1. Central path review done for ipi/nivo while other datasets relied on local path report 2. IO/VEGF with very short f/u and thus wide CIs 3. Ipi/nivo notable for high CR rate and high landmarks with long f/u 4. No detailed CLEAR data

WE DID IT !!! great audience at our last IC course on Minimally Invasive Partial Nephrectomy at SIU-Urology Thanks Alexis Rompré-Brodeur Rafael Sanchez-Salas A Hernandez Porras Florencia Frascheri

Prostate Gland Ablation with HIFU has a mild and transient impact on QoL outcomes at 1 mo, but no impact on QoL at 12 mo post-op. Our McGill initial experience is out: Joseph Moryousef David Bouhadana Gautier Marcq Alexis Rompré-Brodeur @BladouFranck Rafael Sanchez-Salas pubmed.ncbi.nlm.nih.gov/38401258/

Thank you to all the faculty for a successful 2-days discussing cancer care in #urology at the 24th Canadian Senior Resident Uro-oncology Course. Canadian Urological Association McGill University Philippe spiess

Great to have Sam S. Chang MD, MBA as our Urologic Oncology visiting Professor McGill University Centre universitaire de santé McGill Opportunities for NMIBC have become endless and research is pushing for more. Combinations are promising!

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert